MOLOGEN AG, DE0006637200

MOLOGEN AG, DE0006637200

09.04.2018 - 11:02:02

MOLOGEN presenting EnanDIM TME Data at AACR 2018

PRESS RELEASE N 7 / 2018 of 09/04/2018

MOLOGEN presenting EnanDIM(R) TME Data at AACR 2018

Berlin, 9 April 2018 - The biopharmaceutical company MOLOGEN AG will present a poster at the AACR Annual Meeting 2018 (American Association for Cancer Research) in Chicago, Illinois, U.S. (14 - 18 April 2018). The poster is featuring data on the impact of EnanDIM(R) on tumor microenvironment (TME) and single-agent antitumor effects shown in various murine tumor models.Abstract details:Abstract number: 5557 Title: "EnanDIM, a family of potent enantiomeric TLR9 agonists, modulate the tumor microenvironment and show single-agent antitumor effects in various syngeneic murine models" Presentation: The Poster Session will take place on Wednesday, 18 April 2018, 8:00 a.m.-12:00 p.m. at McCormick Place South, Exhibit Hall A, Poster Section 25 (Poster Board Number 13).

For more information on AACR 2018 please visit the website: www.aacr.org

MOLOGEN AG MOLOGEN AG is a biopharmaceutical company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.

The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead product candidate lefitolimod and the next-generation molecule family EnanDIM(R).

The immunotherapeutic agent lefitolimod is the company's lead product candidate and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in small cell lung cancer have been announced in April 2017, and the final analysis in the first quarter 2018 confirmed the data. Furthermore, data from the extension phase of the TEACH study in HIV have also been published in 2017. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy(R)) in various cancer indications. Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.

MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200, SIN 663720) are listed in the Prime Standard of the German Stock Exchange.

www.mologen.com

ContactClaudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com

Note about risk for future predictionsCertain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

 

09.04.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin

Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: presse@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange   End of News DGAP News Service

672381  09.04.2018 

@ dgap.de

Amazon wird sich schwarzärgern, aber …

… wir schenken Ihnen den Report „Börsenpsychologie - Markttechnik für Trader“ heute trotzdem kostenfrei. Normalerweise kostet der Report im Onlinehandel 39,99 Euro.

Sie können sich den genialen Report heute jedoch absolut kostenfrei sichern. Wir senden Ihnen den Report vollkommen KOSTENFREI zu.

Jetzt HIER klicken und dank richtigen Timing reich an der Börse werden!

Weitere Meldungen

MOLOGEN AG plant der ordentlichen Hauptversammlung 2018 eine vereinfachte Kapitalherabsetzung vorzuschlagen. MOLOGEN AG plant der ordentlichen Hauptversammlung 2018 eine vereinfachte Kapitalherabsetzung vorzuschlagen MOLOGEN AG plant der ordentlichen Hauptversammlung 2018 eine vereinfachte Kapitalherabsetzung vorzuschlagen (Boerse, 26.04.2018 - 14:47) weiterlesen...

MOLOGEN erreichte 2017 wichtige strategische Meilensteine und setzt Kapitalmaßnahmen erfolgreich um. MOLOGEN erreichte 2017 wichtige strategische Meilensteine und setzt Kapitalmaßnahmen erfolgreich um MOLOGEN erreichte 2017 wichtige strategische Meilensteine und setzt Kapitalmaßnahmen erfolgreich um (Boerse, 25.04.2018 - 07:16) weiterlesen...

MOLOGEN AG: Bekanntgabe der neuen Termine für die Veröffentlichung des Jahresabschlusses 2017 und die Hauptversammlung 2018. MOLOGEN AG: Bekanntgabe der neuen Termine für die Veröffentlichung des Jahresabschlusses 2017 und die Hauptversammlung 2018 MOLOGEN AG: Bekanntgabe der neuen Termine für die Veröffentlichung des Jahresabschlusses 2017 und die Hauptversammlung 2018 (Boerse, 23.04.2018 - 08:59) weiterlesen...

Vorstandsvorsitzende der MOLOGEN AG wird im Oktober 2018 auslaufendes Vorstandsmandat nicht verlängern. Vorstandsvorsitzende der MOLOGEN AG wird im Oktober 2018 auslaufendes Vorstandsmandat nicht verlängern Vorstandsvorsitzende der MOLOGEN AG wird im Oktober 2018 auslaufendes Vorstandsmandat nicht verlängern (Boerse, 20.04.2018 - 19:15) weiterlesen...

MOLOGEN AG: Zusammenarbeit mit Lizenzpartner ONCOLOGIE nimmt Fahrt auf. MOLOGEN AG: Zusammenarbeit mit Lizenzpartner ONCOLOGIE nimmt Fahrt auf MOLOGEN AG: Zusammenarbeit mit Lizenzpartner ONCOLOGIE nimmt Fahrt auf (Boerse, 20.04.2018 - 12:53) weiterlesen...